DK2827862T3 - Formuleringer af bendamustin - Google Patents

Formuleringer af bendamustin Download PDF

Info

Publication number: DK2827862T3
Authority: DK; Denmark
Prior art keywords: bendamustine; formulations
Prior art date: 2012-03-20

Application number

DK13764989.3T

Other languages

English (en)

Inventor

Srikanth Sundaram

Original Assignee

Eagle Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-20

Filing date

2013-03-15

Publication date

2024-02-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2827862(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-15 Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc

2024-02-12 Application granted granted Critical

2024-02-12 Publication of DK2827862T3 publication Critical patent/DK2827862T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

DK13764989.3T 2012-03-20 2013-03-15 Formuleringer af bendamustin DK2827862T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261613173P	2012-03-20	2012-03-20
US201261669889P	2012-07-10	2012-07-10
PCT/US2013/032289 WO2013142358A1 (en)	2012-03-20	2013-03-15	Formulations of bendamustine

Publications (1)

Publication Number	Publication Date
DK2827862T3 true DK2827862T3 (da)	2024-02-12

Family

ID=49212372

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK13764989.3T DK2827862T3 (da)	2012-03-20	2013-03-15	Formuleringer af bendamustin

Country Status (15)

Country	Link
US (20)	US9034908B2 (da)
EP (2)	EP4360621A3 (da)
JP (8)	JP6250628B2 (da)
CN (1)	CN104302291A (da)
CA (1)	CA2867295C (da)
DK (1)	DK2827862T3 (da)
ES (1)	ES2972227T3 (da)
FI (1)	FI2827862T3 (da)
HR (1)	HRP20240056T1 (da)
HU (1)	HUE064884T2 (da)
PL (1)	PL2827862T3 (da)
PT (1)	PT2827862T (da)
RS (1)	RS65177B1 (da)
SI (1)	SI2827862T1 (da)
WO (1)	WO2013142358A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011094565A1 (en)	2010-01-28	2011-08-04	Eagle Pharmaceuticals, Inc.	Formulations of bendamustine
US20230241218A1 (en) *	2012-07-10	2023-08-03	Eagle Pharmaceuticals, Inc.	Formulations of bendamustine
PL3533447T3 (pl)	2012-03-20	2023-07-17	Eagle Pharmaceuticals, Inc.	Ciekłe kompozycje bendamustyny do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
JP6250628B2 (ja) *	2012-03-20	2017-12-20	イーグル・ファーマシューティカルズ・インコーポレーテッド	ベンダムスチンの製剤
CA2922099C (en)	2013-08-27	2022-11-29	Vasilios VOUDOURIS	Bendamustine pharmaceutical compositions
CN105726472B (zh) *	2016-03-25	2019-12-13	南京康玻斯医药科技有限公司	苯达莫司汀药剂组合物及应用
US11826466B2 (en)	2016-08-31	2023-11-28	Navinta, Llc	Bendamustine solution formulations
US10905677B2 (en)	2016-08-31	2021-02-02	Navinta, Llc	Bendamustine solution formulations
US12246007B2 (en)	2018-08-17	2025-03-11	Hospira Australia Pty Ltd	Liquid bendamustine pharmaceutical compositions
US11730815B2 (en)	2018-11-26	2023-08-22	Good Health, Llc	Stable liquid pharmaceutical compositions comprising bendamustine
WO2020236150A1 (en) *	2019-05-20	2020-11-26	MAIA Pharmaceuticals, Inc.	Ready-to-use bivalirudin compositions
US11992514B2 (en)	2019-05-20	2024-05-28	MAIA Pharmaceuticals, Inc.	Ready-to-use bivalirudin compositions
EP4134068A4 (en) *	2020-04-09	2024-02-07	Bika Biotechnology (Guangzhou) Co., Ltd.	Bendamustine composition and use thereof
US11707450B1 (en)	2022-03-03	2023-07-25	Slayback Pharma Llc	Stable pharmaceutical compositions of bendamustine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE159289C (da)	1903-10-08	1905-03-16
US4071620A (en)	1977-01-10	1978-01-31	American Home Products Corporation	Stabilization of oxygen sensitive dose forms
DD159289A1 (de)	1981-06-01	1983-03-02	Uwe Olthoff	Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de)	1984-12-21	1986-07-10	Merckle Gmbh	Fluessige diclofenac-zubereitungen
US4879286A (en)	1987-01-28	1989-11-07	Lyphomed, Inc.	Cyclophosphamide
US5223515A (en)	1988-08-18	1993-06-29	Takeda Chemical Industries, Ltd.	Injectable solution containing a pyridyl methylsulfinylbenzimidazole
MX9602955A (es)	1994-01-24	1997-06-28	Procter & Gamble	Procedimiento para solubizar activos farmaceuticos dificilmente solubles.
CN1261803A (zh)	1997-07-01	2000-08-02	埃瑟若詹尼克斯公司	抗氧化剂增强对细胞过度增生性疾病的治疗
KR100627614B1 (ko)	1998-04-20	2006-09-25	에자이 가부시키가이샤	안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
AUPQ849900A0 (en)	2000-06-30	2000-07-27	Dbl Australia Pty Ltd.	Injectable composition
AU2001211213A1 (en)	2000-10-20	2002-04-29	Galephar M/F	Stable oral formulation containing benzimidazole derivative
TWI307277B (en)	2002-07-30	2009-03-11	Wyeth Corp	Parenteral formulations
US20060035945A1 (en)	2003-05-30	2006-02-16	Giorgio Attardo	Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
CA2585659A1 (en)	2004-11-05	2006-06-22	Cephalon, Inc.	Cancer treatments
JP2008520652A (ja)	2004-11-22	2008-06-19	ヴィーナス・レメディーズ・リミテッド	非水性液状の非経口的アセクロフェナク製剤
US8436190B2 (en)	2005-01-14	2013-05-07	Cephalon, Inc.	Bendamustine pharmaceutical compositions
AU2006235183B2 (en)	2005-04-08	2011-02-10	Amylin Pharmaceuticals, Llc	Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
AU2007285215A1 (en)	2006-08-14	2008-02-21	Eisai R & D Management Co., Ltd.	Stable lyophilized preparation
EP2073802A1 (en)	2006-10-12	2009-07-01	Astex Therapeutics Limited	Pharmaceutical combinations
US8414909B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
DE102007003184A1 (de)	2007-01-22	2008-07-24	Orlowski, Michael, Dr.	Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en)	2007-09-25	2009-03-26	Protia, Llc	Deuterium-enriched bendamustine
AR072777A1 (es)	2008-03-26	2010-09-22	Cephalon Inc	Formas solidas de clorhidrato de bendamustina
CN102164579B (zh)	2008-09-25	2014-10-15	赛福伦公司	苯达莫司汀的液体配制品
EP2387400A1 (en)	2009-01-15	2011-11-23	Cephalon, Inc.	Novel forms of bendamustine free base
NO2792369T3 (da)	2009-02-25	2018-09-15
US20100273730A1 (en)	2009-04-27	2010-10-28	Innopharmax, Inc.	Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
WO2010126676A1 (en) *	2009-04-28	2010-11-04	Cephalon, Inc.	Oral formulations of bendamustine
CN101584668A (zh)	2009-06-19	2009-11-25	江苏奥赛康药业有限公司	盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en)	2009-06-19	2010-12-23	Lyotropic Therapeutics, Inc.	Pharmaceutical formulations with low aqueous levels of free unbound drug
US8389558B2 (en)	2009-07-20	2013-03-05	Supratek Pharma Inc.	Bendamustine amphiphilic anionic compositions
US20110015245A1 (en)	2009-07-20	2011-01-20	Valery Alakhov	Bendamustine amphiphilic cationic compositions
US7772274B1 (en)	2009-10-19	2010-08-10	Scidose, Llc	Docetaxel formulations with lipoic acid
WO2011094565A1 (en)	2010-01-28	2011-08-04	Eagle Pharmaceuticals, Inc.	Formulations of bendamustine
WO2011103150A2 (en) *	2010-02-18	2011-08-25	Cephalon, Inc.	Lyophilized preparations of bendamustine
CN103002738A (zh)	2010-05-21	2013-03-27	英特利凯恩有限责任公司	用于激酶调节的化学化合物、组合物和方法
WO2012015810A2 (en)	2010-07-28	2012-02-02	Eagle Pharmaceuticals, Inc.	Pharmaceutical compositions containing pemetrexed having extended storage stability
CN104105708B (zh)	2011-12-05	2018-04-03	X博迪生物科学公司	PDGF受体β结合多肽
WO2013112762A1 (en) *	2012-01-24	2013-08-01	Innopharma, Inc.	Bendamustine compositions and methods therefore
KR101951319B1 (ko) *	2012-02-07	2019-02-22	삼성전자주식회사	가변 초점 렌즈
WO2013123227A1 (en) *	2012-02-14	2013-08-22	Eagle Pharmaceuticals, Inc.	Formulations of bendamustine
PL3533447T3 (pl) *	2012-03-20	2023-07-17	Eagle Pharmaceuticals, Inc.	Ciekłe kompozycje bendamustyny do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
JP6250628B2 (ja) *	2012-03-20	2017-12-20	イーグル・ファーマシューティカルズ・インコーポレーテッド	ベンダムスチンの製剤
US9587397B1 (en) *	2015-09-29	2017-03-07	John Milner McCary, SR.	Insulating and support assembly
US10052372B2 (en) *	2016-05-24	2018-08-21	Tessa Therapeutics Pte Ltd	T cell expansion

2013
- 2013-03-15 JP JP2015501813A patent/JP6250628B2/ja active Active
- 2013-03-15 HR HRP20240056TT patent/HRP20240056T1/hr unknown
- 2013-03-15 CN CN201380023657.3A patent/CN104302291A/zh active Pending
- 2013-03-15 US US13/838,090 patent/US9034908B2/en active Active
- 2013-03-15 PL PL13764989.3T patent/PL2827862T3/pl unknown
- 2013-03-15 PT PT137649893T patent/PT2827862T/pt unknown
- 2013-03-15 ES ES13764989T patent/ES2972227T3/es active Active
- 2013-03-15 SI SI201332072T patent/SI2827862T1/sl unknown
- 2013-03-15 HU HUE13764989A patent/HUE064884T2/hu unknown
- 2013-03-15 EP EP23218288.1A patent/EP4360621A3/en active Pending
- 2013-03-15 DK DK13764989.3T patent/DK2827862T3/da active
- 2013-03-15 FI FIEP13764989.3T patent/FI2827862T3/fi active
- 2013-03-15 WO PCT/US2013/032289 patent/WO2013142358A1/en not_active Ceased
- 2013-03-15 CA CA2867295A patent/CA2867295C/en active Active
- 2013-03-15 EP EP13764989.3A patent/EP2827862B1/en active Active
- 2013-03-15 RS RS20240115A patent/RS65177B1/sr unknown
- 2013-12-05 US US14/098,094 patent/US20140094496A1/en not_active Abandoned
- 2013-12-05 US US14/097,904 patent/US20140275196A1/en not_active Abandoned
2015
- 2015-05-18 US US14/714,578 patent/US9144568B1/en active Active
- 2015-09-17 US US14/857,064 patent/US9597397B2/en active Active
2016
- 2016-01-28 US US15/008,819 patent/US9597398B2/en active Active
- 2016-01-28 US US15/008,827 patent/US9597399B2/en active Active
- 2016-06-16 US US15/184,464 patent/US9572887B2/en active Active
- 2016-06-16 US US15/184,488 patent/US9572888B2/en active Active
2017
- 2017-02-14 US US15/432,378 patent/US10052385B2/en active Active
- 2017-11-22 JP JP2017224298A patent/JP6570601B2/ja active Active
2018
- 2018-02-28 US US15/908,075 patent/US20180185488A1/en not_active Abandoned
- 2018-08-08 US US16/058,416 patent/US20180369383A1/en not_active Abandoned
2019
- 2019-03-04 US US16/291,401 patent/US20190192659A1/en not_active Abandoned
- 2019-08-06 JP JP2019144489A patent/JP2019214592A/ja not_active Withdrawn
- 2019-09-30 US US16/588,002 patent/US20200282057A1/en not_active Abandoned
- 2019-11-26 US US16/696,421 patent/US20200368355A1/en not_active Abandoned
2020
- 2020-05-08 US US16/869,875 patent/US20210106686A1/en not_active Abandoned
2021
- 2021-07-30 JP JP2021125009A patent/JP7133070B2/ja active Active
2022
- 2022-02-24 US US17/679,883 patent/US20220323584A1/en not_active Abandoned
- 2022-05-10 US US17/740,990 patent/US20220265829A1/en not_active Abandoned
- 2022-06-30 JP JP2022105476A patent/JP2022130629A/ja active Pending
- 2022-06-30 JP JP2022105477A patent/JP2022130630A/ja active Pending
- 2022-07-25 JP JP2022117843A patent/JP2022141895A/ja active Pending
2023
- 2023-04-05 US US18/296,290 patent/US20230285563A1/en not_active Abandoned
2024
- 2024-01-24 JP JP2024008381A patent/JP2024045290A/ja active Pending
2025
- 2025-09-04 US US19/318,808 patent/US20260000767A1/en active Pending

Also Published As

Publication number	Publication date
US20230285563A1 (en)	2023-09-14
US20160000759A1 (en)	2016-01-07
JP7133070B2 (ja)	2022-09-07
US9144568B1 (en)	2015-09-29
US9572888B2 (en)	2017-02-21
US20260000767A1 (en)	2026-01-01
SI2827862T1 (sl)	2024-03-29
EP2827862A4 (en)	2015-11-18
JP2022130630A (ja)	2022-09-06
FI2827862T3 (fi)	2024-02-13
JP6570601B2 (ja)	2019-09-04
US9597397B2 (en)	2017-03-21
ES2972227T3 (es)	2024-06-11
PL2827862T3 (pl)	2024-05-06
US20130253025A1 (en)	2013-09-26
US9597399B2 (en)	2017-03-21
US20220323584A1 (en)	2022-10-13
EP4360621A2 (en)	2024-05-01
CN104302291A (zh)	2015-01-21
US20220265829A1 (en)	2022-08-25
US20200282057A1 (en)	2020-09-10
US10052385B2 (en)	2018-08-21
US20160296622A1 (en)	2016-10-13
PT2827862T (pt)	2024-03-06
US20160144035A1 (en)	2016-05-26
RS65177B1 (sr)	2024-03-29
EP2827862A1 (en)	2015-01-28
US9597398B2 (en)	2017-03-21
US20190192659A1 (en)	2019-06-27
WO2013142358A1 (en)	2013-09-26
US20180185488A1 (en)	2018-07-05
US20140275196A1 (en)	2014-09-18
HUE064884T2 (hu)	2024-04-28
JP2015510939A (ja)	2015-04-13
JP6250628B2 (ja)	2017-12-20
US9034908B2 (en)	2015-05-19
US20150250766A1 (en)	2015-09-10
US20140094496A1 (en)	2014-04-03
JP2022130629A (ja)	2022-09-06
US20180000938A1 (en)	2018-01-04
JP2021178846A (ja)	2021-11-18
US20160144034A1 (en)	2016-05-26
EP4360621A3 (en)	2024-05-22
CA2867295A1 (en)	2013-09-26
US9572887B2 (en)	2017-02-21
HRP20240056T1 (hr)	2024-03-29
JP2018070624A (ja)	2018-05-10
JP2022141895A (ja)	2022-09-29
EP2827862B1 (en)	2023-12-27
US20200368355A1 (en)	2020-11-26
US20180369383A1 (en)	2018-12-27
US20160296621A1 (en)	2016-10-13
US20210106686A1 (en)	2021-04-15
JP2024045290A (ja)	2024-04-02
CA2867295C (en)	2020-08-11
JP2019214592A (ja)	2019-12-19

Publication	Publication Date	Title
DK2827862T3 (da)	2024-02-12	Formuleringer af bendamustin
DK2528602T4 (da)	2020-04-27	Formuleringer af bendamustin
EP2814487A4 (en)	2015-07-15	FORMULAS FROM BENDAMUSTIN
SMT201700094B (it)	2017-03-08	Composto di pirazina carbossammide
DK3725778T3 (da)	2021-09-20	Formuleringer af enzalutamid
DK3450434T3 (da)	2021-05-03	Deutererede derivater af ruxolitinib
DK3336097T3 (da)	2020-09-28	Fremstilling af ikke-krystallinsk obeticholsyre
CO7061086A2 (es)	2014-09-19	Combinaciones de compuestos activos
DK2845905T3 (da)	2021-06-14	Fremstilling af oligosaccharider
DK2968529T3 (da)	2020-10-12	Fremstilling af jordnøddeformuleringer til oral desensibilisering
PT2648520T (pt)	2018-06-06	Formulação de pré-mistura de dexmedetomidina
DK2846809T3 (da)	2021-01-18	Behandling af myelosuppression
DK2981255T3 (da)	2022-11-14	Terapeutiske anvendelser af empagliflozin
DK2968221T3 (da)	2019-08-05	Farmaceutisk sammensætning af s-ketaminhydrochlorid
AR092198A1 (es)	2015-04-08	Derivados de pirazolopirimidinas
DK3106150T3 (da)	2021-11-01	Forbedrede farmaceutiske sammensætninger af pimobendan
EP2906040A4 (en)	2016-07-06	Novel benzimidazoletetrahydropyran derivatives
HRP20160908T1 (hr)	2016-09-23	Biciklički derivati pirazinona
HRP20190173T1 (hr)	2019-03-22	Oralne formulacije deferasiroksa
EP2925325A4 (en)	2016-07-13	STABILIZED FORMULATION OF PEMETREXED
DK2822568T3 (da)	2020-08-10	Anvendelser af caseinsammensætninger
EP2888965A4 (en)	2016-05-11	KIMONO
DK2925338T3 (da)	2019-05-06	Frysetørret formulering af tat-nr2b9c
DK2919777T3 (da)	2020-03-09	Transmukosal afgivelse af tocotrienol
EP2818015A4 (en)	2016-08-31	Managing wireless area networks